Metatron (MRNJ) Now Accepts BitCoin Cryptocurrency and
Update on BitWeed Marijuana Payments App
Dover, DE -- December 11, 2017 -- InvestorsHub NewsWire --
Metatron (OTC:
MRNJ), a technology pioneer specializing in the accelerated
release of over 2000 apps including Cannabis based, CBD, and
Vaporized secure chat apps via iTunes and Google Play, is pleased
to report the final stage development of Bitweed, a cryptocurrency
transaction and tracking app for Marijuana dispensaries and
consumers.
A biotech company now distributes the Metatron developed and
recent updated Cannaboids app under its own iTunes account with
Google Play soon to follow.
"Bitcoin has risen 1500% this year,
about 85% in the last few weeks and Futures contracts open as of
yesterday . With Cannabis legal in about 29 states, and Canada
making recreational Marijuana legal, both industries are now
mainstream. Payment solutions are needed for dispensaries and
customers so we plan on integrating the upcoming Bitweed and the
popular Cannaboids apps to make this process more efficient for
retailers and consumers We expect Bitweed to eventually evolve into
its own cryptocoin"" said CEO Joe Riehl
New Alliance Biosciences, Inc., formerly Sanguine Corporation
(through its subsidiary, SGN LifeSciences, is engaged in
discovering, developing and commercializing novel
biotechnologies.
The company is focused on the development and commercialization
of perfluorocarbon based therapeutic oxygen carriers. The Company's
core product, PHER-02, is a perfluorocarbon emulsion.
Our two companies plan to conduct a shared roll-out of mobile
applications geared to solve issues in the cannabis payment space
using Blockchain technology and Bitcoin options. These apps will be
marketed under Cannaboids (www.cannaboids.com), and Bitweed
brands while New Alliance provides necessary biotech and medical
research for Metatron (www.Metatroninc.com) bio-tech app
development.
This announcement coincides with the launch of http://www.icocryptoblockchain.com, the premier
one-stop website soon to be app with the latest cryptocurrency
news, education, editorials, market capitalizations, trade volume
and ICO alerts.
"This is a unique animal unlike any commodity we've looked at
before," said Andrew Busch, the CFTC's chief market intelligence
officer.
According to industry estimates, Bitcoin and the over 1000 other
cryptocoins are now worth over $300 billion, only a year ago they
were worth about 1 Billion. Today $10 billion+ in digital tokens
change hands daily and even big players such as Goldman Sachs,
Visa, Capital One, Nasdaq, and the New York Stock Exchange have
invested in blockchain technology. We expect Bitcoin market cap to
surpass the S&P index and eventually even Gold trading in
overall value.
According to Forbes By 2020, the Cannabis industry is expected
to create more jobs than manufacturing. Overall legal marijuana
sales are set to increase from about 7 billion dollars in 2016 to
26.5 billion dollars 2020. Since Canada recently legalized
recreational marijuana nationwide, it will result in an additional
23 Billion dollar added to the industry over the same time period
according to Delotte.
Metatron an industry leader in the field of mobile app
development with over 2000 apps created, millions in sales and
downloads historically, has partnered with high profile companies
and clients worldwide and is poised to revolutionize the exploding
crypto and cannabis industries.
Through its app development division i-Mobilize, and as a
pioneer in emerging markets, Metatron was the first company to
release any Cannabis related apps on iTunes and has extensive
experience in processing payments through its Just Data Billing
division. Release date for the BitWeed app is expected first
quarter of next year.
Metatron is also pleased to announce a formal offer to
Buzzlink.com, a cannabis e-commerce platform for dispensaries and
other retailers. Buzzlink.com will be financed partially by the
issuance of preferred B series shares and we now accept Bitcoin,
soon other Coins.
Metatron approved investors can acquire Series B shares in
blocks of various sizes. The first round investors will receive the
highest discount. Series B shares can be redeemed through the
Company, are immune to reverse splits, and will convert at 1 B
share to 50,000 common shares at a discount. There are a limited
number of B shares available and Metatron reserves the right to end
offering at any time.
Details available at:
http://metatroninc.com/series-b/
Metatron's Apps:
iTunes: https://itunes.apple.com/us/artist/i-mobilize-inc./id325075390
Google Play: https://play.google.com/store/apps/developer?
id=Metatron+Inc
Facebook: http://www.facebook.com/metatroninc
Twitter: http://twitter.com/metatroninc
News: http://metatroninc.com/blog
Correction from last PR:
In our last press release we referred to Sanguine BioSciences
website (www.sanguinebio.com) and company in error and
our app contract is with Sanguine inc. Sanguine inc. had a recent
name change and is the same space. We are not affiliated or have
any business with the Sanguine Biosciences , and updated our
various news channels as soon as it was brought to our
attention.
Forward-Looking Statements:
Any statements made in this press release which are not
historical facts contain certain forward-looking statements, as
such term is defined in the Private Litigation Reform Act of 1995,
concerning potential developments affecting the business,
prospects, financial condition and other aspects of the company to
which this release pertains. These forward-looking statements
involve known and unknown risks, uncertainties and other factors
that may cause our actual results of the specific items described
in this release, and the company's operations generally, to differ
materially from what is projected in such forward-looking
statements. Although such statements are based upon the best
judgments of management of the company as of the date of this
release, significant deviations in magnitude, timing and other
factors may result from business risks and uncertainties including,
without limitation, the company's need for additional financing,
which is not assured and which may result in dilution of
shareholders, the company's status as a small company with a
limited operating history, dependence on third parties and the
continuing popularity of the iOS/Android operating systems, general
market and economic conditions, technical factors, receipt of
revenues, and other factors, many of which are beyond the control
of the company. Although we believe that the expectations and
statements reflected in the forward-looking statements are
reasonable and accurate at time of release, we cannot guarantee
future results, levels of activity, performance, or achievements.
Moreover, neither we nor any other person assumes responsibility
for the accuracy and completeness of such statements, and we
disclaim any obligation or liability to update information
contained in any forward-looking statement or errors in press
releases. Metatron does not grow, sell or distribute any substances
that violate United States Law or the Controlled Substances
Act.
Metatron, Inc. 302-861-0431 ir@metatroninc.com SOURCE: Metatron,
Inc